InsiderTrades

Form 4 for IONS IONIS PHARMACEUTICALS INC

Accepted 2026-05-15 18:15:03 ET · period of report 2026-05-13 · accession 0000874015-26-000185 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-05-15 18:15 2026-05-13+ IONS Monia Brett P CEO, Dir M - OptEx $32.60 +4,536 245.9K +2% +$147.9K
DMT 2026-05-15 18:15 2026-05-13+ IONS Monia Brett P CEO, Dir S - Sale+OE $78.49 -4,536 242.7K -2% -$356.0K
DMT 2026-05-15 18:15 2026-05-13+ IONS Monia Brett P CEO, Dir M - OptEx $0.00 -4,536 35.6K -11% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-05-13 M A 1,316 $32.60 243,978 D — —
2 Common Common Stock 2026-05-13 S D 1,316 $78.01 242,662 D — — (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
3 Common Common Stock 2026-05-14 M A 3,220 $32.60 245,882 D — —
4 Common Common Stock 2026-05-14 S D 3,220 $78.68 242,662 D — — (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
5 Derivative Non-Qualified Stock Option (right to buy) 2026-05-13 M D 1,316 $0.00 38,857 D $32.60 · 2023-01-03 to 2032-01-02 1,316 Common Stock
6 Derivative Non-Qualified Stock Option (right to buy) 2026-05-14 M D 3,220 $0.00 35,637 D $32.60 · 2023-01-03 to 2032-01-02 3,220 Common Stock